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ABSTRACT  
Ample evidence identifies strong links between major depressive disorder (MDD) and both risk of 
ischemic or coronary heart disease (CHD) and resultant morbidity and mortality. The molecular 
mechanistic bases of these linkages are poorly defined. Systemic factors linked to MDD, including 
vascular dysfunction, atherosclerosis, obesity and diabetes, together with associated behavioural 
changes, all elevate CHD risk. Nonetheless, experimental evidence indicates the myocardium is 
also directly modified in depression, independently of these factors, impairing infarct tolerance and 
cardioprotection. It may be that MDD effectively breaks the heart’s intrinsic defense mechanisms. 
Four extrinsic processes are implicated in this psycho-cardiac coupling, presenting potential targets 
for therapeutic intervention if causally involved: sympathetic over-activity vs. vagal under-activity, 
together with hypothalamic-pituitary-adrenal (HPA) axis and immuno-inflammatory dysfunctions. 
However, direct evidence of their involvement remains limited, and whether targeting these 
upstream mediators is effective (or practical) in limiting the cardiac consequences of MDD  is 
unknown. Detailing myocardial phenotype in MDD can also inform approaches to cardioprotection, 
yet cardiac molecular changes are similarly ill defined. Studies support myocardial sensitization to 
ischemic insult in models of MDD, including worsened oxidative and nitrosative damage, apoptosis 
(with altered Bcl-2 family expression) and infarction. Moreover, depression may de-sensitize hearts 
to protective conditioning stimuli. The mechanistic underpinnings of these changes await 
delineation. Such information not only advances our fundamental understanding of psychological 
determinants of health, but also better informs management of the cardiac consequences of MDD 
and implementing cardioprotection in this cohort. 
 
Keywords:  Cardioprotection; Chronic Stress; Major Depressive Disorder; Ischemic Heart Disease; 
Myocardial Infarction 
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1. Introduction 
Major depressive disorder (MDD) shares a reciprocal relationship with coronary heart 
disease (CHD) (reviewed in [1-3]). This behavioral disorder places healthy individuals at increased 
risk of CHD [4-7], is strongly linked to CHD in those with or without existing cardiac disease [6,8-
10], is an independent risk factor for cardiovascular mortality and morbidity [11-13], and is more 
prevalent in those who have suffered AMI [12,14]. As a CHD risk factor, MDD exerts an impact 
similar to conventional determinants (eg.  smoking, elevated cholesterol, hypertension, diabetes) 
[15,16], and increases the risk of recurrent cardiac events and death in those with CHD by up to 4-
fold [11,17,18]. The magnitude of CHD risk is also related to the severity of MDD, ranging from a 
2-fold increase to up to 5-fold with more severe depression [7]. Depression thus appears as 
powerful a determinant of CHD risk and outcomes as more traditional risk factors, and its 
occurrence is significant: recent analyses indicate a lifetime prevalence of ~16% in the US [19], 
with varying estimates from other populations (and diagnostic criteria), for example ~11% in 
Canada [20], 4-7% in Singapore [21], 12% in a Scottish cohort [22], 18% in urban Ethiopians [23], 
and 5% in rural-to-urban Chinese workers [24]. Whether overall incidence is on the rise is 
questionable, with a perceived growing epidemic of MDD and anxiety disorders potentially 
reflecting population growth, among other factors [25]. Whether more extensive ‘sub-threshold’ 
depression influences CHD risk and outcomes is also unclear. 
As opposed to most major CHD risk factors, the biological mechanisms linking depressive 
disorders and heart disease remain to be detailed. From a holistic perspective [reviewed in 2,26], 
depressive and chronic heart disorders share the same physiological network of mechanisms (thus 
risk factors). This Psycho-Immune-Neuroendocrine (PINE) network is predicated on key regulatory 
systems [26], including the autonomic nervous, immune and endocrine systems, and components of 
the central nervous system (Figs. 1 & 2). Perturbation of the regulatory PINE network may 
predispose an individual to both MDD and CHD, with onset of either disease (and manifestation of 
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one ahead of the other) influenced by hereditary and environmental factors [26] (Fig. 1). 
Highlighted in Fig. 1, there is a high degree of bidirectional interconnectedness between CHD and 
MDD – common mechanistic elements are implicated in both scenarios, and pathologic outcomes 
of each exert positive feedbacks on the other. For example, MDD may promote cardiac dysfunction 
via intermediate pathological and physiological mechanisms: behavioral changes with MDD 
contribute to inactivity, in turn promoting obesity, dyslipidemia, type 2 diabetes and hypertension, 
while associated social isolation additionally worsens CHD risk and mortality. There is also 
evidence that disruption of the PINE network can physiologically promote risk of dyslipidemia, 
type 2 diabetes and hypertension, and thus CHD [26]. The same intermediary pathologies can 
equally contribute to MDD.  
Although now a well-recognized and clinically important manifestation of psycho-cardiac 
coupling, and while the PINE network model provides a framework for understanding depression-
dependent changes in CHD risk and outcomes [26], relatively few studies have investigated the 
molecular mechanistic basis of these interactions. In particular, how the heart itself is intrinsically 
modified by depression remains to be fully detailed. Certainly, co-morbidities associated with or 
promoted by MDD, including obesity, diabetes and aging, are known to negatively impact 
myocardial stress-resistance and cardioprotection [27-30]. However, experimental evidence reveals 
that chronic stress and MDD directly impair myocardial capacity to withstand injury/infarction 
independently of these systemic factors. This review focuses on these direct myocardial impacts of 
depression, specifically the heart’s capacity to withstand damage with infarction and respond to 
protective intervention. Not only contributing to worsened CHD risk and outcomes, depression may 
simultaneously render the heart resistant to cardioprotective interventions. While Tako-Tsubo 
cardiomyopathy exemplifies the notion of a ‘broken heart', evidence suggests depression may 
effectively break the heart’s intrinsic defense mechanisms, thus ability to withstand cellular injury 
and death. Beyond accumulating epidemiological evidence, and development of frameworks with 
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which to test and unravel these interactions [2,26] (Fig. 1), the molecular bases of these myocardial 
changes await more detailed investigation (Fig. 2).    
 
2.  Impacts of depression on myocardial infarction  
2.1 Pre-ischemic depression 
 It is only relatively recently that studies have examined the detrimental impacts of stress and 
MDD on the heart’s response to ischemic insult or infarction. Data generated in the landmark 
Whitehall study revealed strong relationships between social stress and metabolic and 
cardiovascular health outcomes [31-33]. In terms of those at risk of AMI, the prevalence of 
depression is significant with approximately 1-in-5 patients referred for diagnostic catheterization 
and angiography suffering pre-existing MDD [8,34], confirming significant prevalence of the 
disorder in those at risk of AMI. Early investigations revealed that depression impairs heart rate 
variability and autonomic control in humans [35], and that chronic stress (inducing depressive 
symptoms) increases heart rate, sympathetic tone, and cardiovascular reactivity to stress in animals 
[36,37], suggesting enhanced cardiac vulnerability to arrhythmia and injury. Further investigations 
over the last 3 decades have largely relied on chronic stress models (eg. subjecting animals to 
physical restraint, social isolation, predation stress, forced swimming, environmental instability, and 
randomized series of such stressors), which exhibit symptoms of depression that may include 
anhedonia and decreases in sexual drive, aggression, investigative behavior and locomotion, 
together with circadian disruption, disordered sleep and weight loss [38,39] (models discussed 
below in section 4). These studies identify both ultrastructural disruption in otherwise healthy hearts 
[40,41] and substantial changes in myocardial injury responses [40,42-47]. However, they have not 
yet developed a mechanistic understanding of these cardiac outcomes. Most research to date has 
focused on key end-points, including cell death, infarction, arrhythmogenesis and stunning, with 
few delving into underlying molecular mechanisms. 
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 Scheuer and Mifflin showed that experimental infarction in rats is significantly worsened by 
daily restraint stress [42]. These investigators had previously identified worsened infarction in 
response to chronically elevated corticosterone [43].  Subsequent work indicates that chronic 
emotional stress exaggerates infarction in rats in association with increases in markers of oxidative 
and nitrosative damage [44]. Ravingerova et al. found chronic stress also increases contractile 
dysfunction and risk of post-ischemic arrhythmias in normotensive rats, though stress somewhat 
paradoxically improved these parameters in hypertensive animals [45]. While emulating post-
traumatic stress disorder (PTSD), a more recent study in a psychosocial predator-based animal 
model reports increases in contractile dysfunction and myocardial death following ischemia, though 
specifically in males and not females [46]. Delving into mechanistic elements, Rakhshan et al. 
found that  chronic physical or psychological stress worsened myocardial damage during infarction, 
and that this effect was eliminated by chemical sympathectomy (without influencing corticosterone 
levels) [47]. While not assessing infarction per se, Xinxing et al. report an association between 
myocardial injury and shifts in adrenaline, noradrenaline, corticosterone and 5-HT in a rat model of 
chronic stress [40]. There is thus some support for sympathetic over-activity and HPA dysfunction 
in myocardial stress intolerance in depressive disorders, though the identities and roles of 
neurohumoral factors involved await confirmation (Fig. 2).  
 There is also relatively little information available regarding the myocardial molecular 
changes that underpin these reductions in ischemic tolerance, with data essentially limited to 
damage markers and expression of pro- and anti-apoptotic Bcl-2 family proteins (Fig. 2). An 
analysis of cardiac and nervous responses reveals induction of Bax and repression of Bcl-xl 
transcripts in a rodent model of depression, potentially predisposing to apoptosis [48]. Subsequent 
investigations from this group confirm shifts in both transcript and protein for apoptotic regulators, 
including increased myocardial Bax, Bcl-2 and Bax/Bcl-2 ratio without changes in caspase-3 in 
rodent models of depression either prior to [49] or following [50] infarction. This may evidence 
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differential activation of caspase-3 independent death pathways with depression: Bax and Bcl2 not 
only modulate caspase-3 dependent apoptosis, but influence mitochondrial respiration, membrane 
permeability, cytochrome c release, and caspase-3 independent death. How these proteomic and cell 
death responses arise remains to be determined, though reported elevations in oxidative and 
nitrosative damage [44] will certainly promote apoptosis and oncosis. Nonetheless, the bases of the 
latter molecular damage outcomes are also unknown – are processes of reactive oxygen or nitrogen 
species generation dysregulated, and/or are anti-oxidant and molecular detoxification and repair 
mechanisms impaired with depression? There is preliminary evidence myocardial anti-oxidants 
levels are suppressed [44] and injurious toll-like receptor 4 and NFkB signaling up-regulated [41] 
with chronic stress, whereas cardioprotective NOS and Akt signaling are only modified by chronic 
stress (crowding) in the hearts of hypertensive and not normotensive rats  [45,51]. Further work 
examining shifts in pro-survival vs. pro-injury signaling pathways across a broader range of models 
may clarify the basis of intrinsically impaired infarct tolerance in depression. 
 Other unknowns include the impacts of differing types and durations of stress. For example, 
while several models of chronic stress detrimentally influence myocardial infarct tolerance, 
crowding stress reportedly fails to modify infarction in hypertensive rats [51], while acute forms of 
stress can be cardioprotective. The latter response, a form of hormesis, is exemplified in the broadly 
conserved pre-conditioning phenomenon - transient ischemia induces powerful protection against 
subsequent prolonged insult. This contrasts the generally detrimental effects of chronic 
psychological stress on myocardial phenotype [52]. Both acute and chronic stressors may influence 
intrinsic myocardial defense mechanisms: chronic metabolic disorders and aging dysregulate 
survival kinase signaling engaged by acute stressors, resulting in impaired infarct tolerance [53,54].  
Physical stress (eg. wheel-running in naïve mice) induces cardioprotection via the same kinase 
signaling [55], and our recent unpublished findings suggest that psychological effects of 
environmental enrichment (placement of a locked running wheel in cages) may similarly boost 
	 8 
infarct tolerance in caged mice, coupled with phospho-regulation of the same survival and stress 
kinases (see preliminary data in Fig. 3). These intriguing observations of acute protection via simple 
environmental enrichment warrant further investigation, highlighting the importance of 
psychological state in dictating myocardial phenotype and also raising questions regarding 
behavioral status in ‘control’ caged rodents. Finally, it is relevant to note there is evidence that the 
impacts of differing types of stress may be sex-dependent, with a model of PTSD selectively 
exaggerating post-ischemic myocardial damage and dysfunction in males only [46], while in 
contrast other stress (eg. crowding, sleep deprivation) worsens ischemic outcomes in females and 
not males [51,56]. 
 From a cellular perspective, depression or chronic stress appears to impact all major 
cardiovascular elements. Studies to date support exaggerated cardiomyocyte apoptosis [40,49] and 
hypertrophy [57-59], together with myocyte abnormalities that include edema, myofibrillar damage 
and changes to mitochondria, nuclei and sarcoplasmic reticulum [40,41]. Myocyte contractile 
properties are also reportedly impaired, in association with depression of Ca2+ levels  [59]. 
Exaggerated myocardial fibrosis, with increased transcripts for collagens, connective tissue growth 
factor and transforming growth factor-β1 [57-59], implicate shifts in cardiac fibroblast 
phenotype/function. Coronary vascular function is also modified, with evidence of impaired 
coronary perfusion [45], while cardiac endothelial cells may also degenerate [41]. Chronic stress 
can also induce vascular stiffening [60], together with potentially adaptive NO generation and 
relaxation [61,62], though these outcomes have not been assessed specifically in coronary vessels. 
Thrombotic processes are also dysregulated, with evidence for involvement of circulating tissue 
factor (not vascular tissue factor, or platelet function) [63], although others report enhanced platelet 
aggregation [64]. Inflammatory and immune function is a key implicated element in the 
cardiovascular sequelae of MDD, and there is evidence for increased inflammatory cell infiltration 
and pro-inflammatory signaling in hearts of chronically stressed animals [41,58]. It thus appears all 
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major cellular elements of the heart, including myocytes, fibroblasts, endothelium and coronary 
vascular cells may be impacted in depression, together with invading or resident 
inflammatory/immune cells, and potentially platelets.    
 
2.2 Post-Ischemic Depression 
 The occurrence of MDD after acute myocardial infarction (AMI) is well established, and is 
associated with both worsened quality of life [65] and higher mortality and rehospitalization [11,66, 
67]. Up to 25% of patients suffer from depression post AMI, which is 2-4 times higher than the 
general population [8,34,68,69]. Though less well studied than the negative impacts of pre-existing 
depression, depression induced after AMI also appears to exaggerate cardiac apoptotic signaling 
and death [50] and tissue remodeling [70]. On the other hand, a recent study of post-infarction 
housing stress in rats found no significant effects on subsequent progression of heart failure [71]. 
Whether myocardial mechanisms underlying the effects of pre- vs. post-infarct depression are 
similar remains to be addressed, though Wang and colleagues find evidence of altered expression of 
apoptosis proteins in both scenarios [49,50].  
  
3. Potential mediators of myocardial infarct intolerance in depression 
 There are 4 inter-related regulatory systems perturbed in MDD that plausibly give rise to 
myocardial intolerance to infarction (Figs. 1 & 2): sympathetic over-activity, vagal dysfunction, 
HPA axis abnormalities, and shifts in immune function and inflammation [2,26]. There is limited 
experimental support for involvement of the former neurohumoral mediators, while roles of 
immune and inflammatory processes have yet to be directly tested. The mechanistic roles of these 4 
regulatory systems thus require more detailed investigation. 
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3.1 Sympathetic over-activity  
 The sympathetic nervous system is an important determinant of cardiovascular disease 
progression [72] and pathogenesis of AMI [73,74]. Individuals suffering depression exhibit 
increased sympathetic activity [74,75], including specifically elevated cardiac sympathetic tone 
[76]. This is also evidenced in reduced heart rate variability in psychological disorders including 
MDD [77-79]. Such autonomic dysfunction has been linked to increased risk of heart disease [80] 
and heart disease mortality and morbidity in MDD [35,81]. At a cellular level chronic sympathetic 
activation can increase oxidative stress and dysregulate apoptotic pathways to worsen myocardial 
injury [82] Sustained release or sudden spikes in catecholamine levels also increase risk of cardiac 
complications such as arrhythmias and sudden cardiac death. Modulation of autonomic nervous 
activity has been shown to reduce myocardial ischemia-reperfusion injury [83-86], and β-blockade 
has been a mainstay in management of patients with CHD/AMI.  
The myocardial effects of sympathetic over-activity are certainly consistent with 
involvement in the negative consequences of MDD (Fig. 2). Increased β-adrenergic receptor 
activity promotes both apoptosis and oncosis [87-90], with pro-death effects potentially involving 
NADPH oxidase activity [91,92], nitric oxide generation and nitrosative stress [93,94], and 
modulation of Bcl-2 protein expression profiles [90,95]. Oxidative stress with noradrenaline has 
also been linked to epigenetic repression of protective PKCε (via NADPH oxidase-1 dependent 
oxidative stress) [96]. Additionally, increased β-adrenergic receptor activity enhances apoptotic 
death in response to immuno-inflammatory activation [95], in association with altered stress kinase 
signaling and Bcl-2 expression. These putative mechanisms are consistent with the elevations in 
myocardial oxidative and nitrosative stress [44], shifts in Bcl-2 proteins and execution of apoptosis 
[47-49], and inflammatory responses [41,58] observed in animal models of depression. Cardiac 
pathologies relevant to risk of and outcomes from AMI have also been linked to β-adrenergic 
receptor activity in models of chronic stress, including hypertrophy, fibrosis, diastolic dysfunction 
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and oxidative stress [58]. 
Although widely assumed, reflecting pro-infarct effects of sympathetic activity in other 
settings, the involvement of sympathetic over-activity in infarct intolerance in MDD has yet to be 
thoroughly tested. Furthermore, whether the degree and pattern of sympathetic activation in animal 
models of depression reflect changes and roles in human MDD is not at all clear. The recent report 
of Rakhshan et al. suggests reduced infarct tolerance in a rat model of chronic stress is blocked by 
chemical sympathectomy [47], consistent with involvement of sympathetic over-activity. Variable 
effects of sympathectomy on infarct tolerance [97-99] nonetheless raise questions regarding 
selectivity and the mechanistic basis of sympathectomy outcomes. That said, studies also confirm 
elevations in circulating noradrenaline and adrenaline in MDD [74-76], and Xinxing et al. recently 
report in vitro cytotoxicity in otherwise healthy cells subjected to changes in noradrenaline, 
corticosterone and 5-HT that mimic those in a rat model of chronic stress [40]. However, the 
involvement of these factors in stress-dependent myocardial changes in vivo has yet to be directly 
tested. For example, a reduction in 5-HT with chronic stress [40] might also promote cell survival 
given recent evidence of 5-HT receptor involvement in cardiac apoptosis and remodeling following 
adrenergic activation [100].  
 It is also important to note that effects of cardiac nerves on ischemic injury are complex, and 
adrenergic receptor sub-types exert distinct effects on myocyte survival vs. death. Regional 
ischemia activates the autonomic nervous system, reducing electrical stability and promoting 
arrhythmias, modifying cardiac O2 supply/demand and worsening myocardial injury. However, 
disrupting extra-cardiac nervous system input can exert either protective [97,98,101] or injurious 
effects [102,103]. Indeed, it has been suggested that absence of cardiac nerve activity may impair 
cardiac functional recovery [104]. In terms of cardioprotection, the second (delayed) but not first 
(acute) window of protection with pre-conditioning may require cardiac nerve activity [105]. Others 
report that surgical denervation does not eliminate pre-conditioning in dogs, yet significantly 
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reduces infarction alone [101]. The cardiac α- and β-adrenergic receptor sub-types activated by 
noradrenaline and adrenaline also exert opposing effects on stress responses and cell death. 
Activation of β-adrenergic receptors can protect against or promote cell death [90], with β1 activity 
contributing to both cardiac apoptosis [90,95,106] and cardioprotection via ischemic 
preconditioning [106-109], while β2 receptor activity may contribute to myocyte survival, ischemic 
tolerance and preconditioning responses [90,110,111]. The α1 adrenergic receptors also exert 
opposing effects, with the higher affinity α1A receptor promoting myocyte survival and ischemic 
tolerance [112-114], contributing to delayed cardioprotection [115], and improved angiogenesis 
[116], remodeling and survival [117] post-infarction. The survival effects of α1A receptor activity 
may involve modulation of Bcl-2 proteins implicated in the pro-apoptotic response to β-adrenergic 
receptor activity, providing a counterbalance to limit apoptosis with sympathetic over-activity.  
Conversely the lower affinity α1B-adrenergic receptor may promote hypertrophy and contractile 
dysfunction [118], and as opposed to the longevity (and anti-cancer) effects of α1A activity, appears 
to reduce lifespan [119]. Thus, sympathetic activation and HPA axis dysfunction may induce 
differential effects on cardiac death, remodeling processes and overall survival, governed by 
adrenergic receptor sub-type expression and activation patterns. These complexities, coupled with 
the limited analyses of sympathetic over-activity to date, indicate more direct and thorough 
assessment is needed to identify roles of sympathetic nervous and humoral signaling in reducing 
myocardial infarct tolerance in MDD (Fig. 2).  
 
3.2 Vagal dysfunction  
 Major depressive disorder is associated with reduced vagal activity, with evidence of a 
causal relationship between vagal function and depression [3,120]. Importantly, vagal dysfunction 
is likely to impair myocardial infarct tolerance, and may also negate capacity to protect the heart of 
MDD patients via widely trialed pre-conditioning interventions (Fig. 1). Detailed below, vagal 
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stimulation and the primary vagal transmitter acetylcholine protect against cardiac and vascular 
injuries, and play an essential role in ischemic pre-conditioning responses (Fig. 2).  
 Early clinical studies identified the importance of autonomic function in mortality following 
AMI [121,122], with experimental studies establishing the role of vagal activity in limiting 
arrhythmogenesis and enhancing survival post-AMI [123-127]. Investigations subsequent to these 
analyses of electrical stability/arrhythmogenesis revealed that acetylcholine and muscarinic receptor 
agonists also protect mammalian myocardium from ischemic injury [128,129], initially implicating 
reactive oxygen species signaling and ATP-gated K+ channel activity [130-133] together with nitric 
oxide [134].  
 Later studies established that vagal stimulation, confirmed to increase cardiac interstitial 
acetylcholine [135], also reduces ischemic damage and infarction [136-139], and improves post-
infarct inflammation and remodeling [140]. The protective effects of vagal activity and 
acetylcholine are not limited to myocardial cells, extending to protection of coronary vascular cells 
[134] and reduction of peripheral vascular inflammation and injury [141] during infarction. Other 
work confirms essential involvement of vagal activity in cardioprotection via remote pre-
conditioning [142,143], with evidence release of the protective factor (which induces protection via 
recruiting intrinsic cardiac ganglia) is dependent upon prior vagal activation [144].  
 Mechanistically, while initial studies focused on roles of reactive oxygen species, KATP 
channels and nitric oxide in the protection elicited by acetylcholine and muscarinic receptors, 
studies also support roles for improved Ca2+ handling [145,146], and the ‘cholinergic anti-
inflammatory pathway’ (involving suppression of JAK-STAT and NFκB signaling) appears key to 
the cardiac and vascular protection with vagal activity (Fig. 2). Acetylcholine modulates myocyte 
expression of inflammatory cytokines [147], and vagal stimulation reduces neutrophil invasion and 
inflammatory markers in post-ischemic myocardium [137], modifies TNF-α expression and 
differentially modulates protective vs. injurious TNF receptor sub-types[138,148], and inhibits 
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expression of injurious Il-17a during infarction [149]. 
  Interestingly, more recent work in cultured cell models of hypoxia/reoxygenation injury 
supports beneficial effects of acetylcholine on autophagy [150], and mitochondrial biogenesis [151] 
and quality control via mitophagy [152]. Similarly, vagal nerve stimulation may limit myocardial 
injury by inhibiting mitochondrial dysfunction and associated apoptosis [139], though this study 
found protection was limited to intra-ischemic intervention while post-ischemic stimulation was 
ineffective. Other work supports vagal control of mitochondrial dynamics, likely promoting stress-
tolerance and limiting cell death [153]. Inhibition of the mitochondrial unfolded protein response 
may additionally contribute to anti-apoptotic effects of acetylcholine, potentially via inhibition of 
mitochondrial oxidant generation [154]. Studies thus collectively reveal important roles for vagal 
activity in dynamic maintenance of mitochondrial phenotype and function. While neuronal 
autophagy appears dysregulated with depression, the effects of  MDD or chronic psychological 
stress on cardiac fission, fusion and mitophagy await analysis. 
 Both muscarinic (M2, M3) receptors and nicotinic receptors may contribute to the protective 
effects of vagal activity and acetylcholine. Studies initially focused on muscarinic M2 receptors, 
with antagonism or knockdown confirming involvement in protection of cardiomyocytes [147,155]. 
Additionally, M3 agonism with choline is cardioprotective [146,156], and the M3 receptor is 
implicated in the anti-apoptotic effects of acetylcholine [154] and in vagally mediated protection 
[133]. Finally, nicotinic receptors may also participate, with the study of Calvillo et al. supporting 
involvement of the nicotinic pathway and inflammatory modulation in cardioprotection via vagal 
stimulation [137]. Activation of the α7nACh receptor also substantially limits inflammation during 
myocardial ischemia-reperfusion [157], and may promote angiogenesis post-infarction [158] (Fig. 
2). 
Despite considerable evidence supporting cardiac protection via vagal activity in other 
settings, no study has yet demonstrated that reduced vagal activity underlies exaggerated 
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myocardial infarction in models of MDD. This is important if vagally targeted therapies were to be 
implemented. Clinically, vagal stimulation has been assessed in chronic heart failure, where it has 
been established as safe and efficacious [159-161]. Trials in myocardial infarction (or surgical 
ischemia) have yet to be undertaken. Among other unknowns, it is unclear whether detrimental 
impacts of sympathetic and vagal dysfunction on infarction and cardioprotective signaling are 
additive or potentially synergistic. It is thus unclear whether combined targeting of vagal and 
sympathetic pathways will be substantially more effective, practical or problematic, in terms of 
protecting against ischemic damage and infarction. We are unaware of studies assessing dual 
treatment via both parasympathetic agonism/nerve stimulation and sympathetic antagonism/nerve 
block. Although in a different setting, combined vagal stimulation and β-blockade has been shown 
to be more effective than either alone in preserving function in a model of chronic heart failure 
[162]. 
 
3.3 The HPA axis  
 The endocrine response to stress involves anterior hypothalamic release of corticotropin-
releasing hormone, and pituitary secretion of adrenocorticotropic hormone to stimulate adrenal 
cortex secretion of glucocorticoids such as cortisol [163]. Chronic stress results in over-secretion of 
glucocorticoids and downstream adrenal catecholamines [164]. Inflammatory dysfunction is an 
important element in MDD, and cytokines also stimulate the HPA axis, with IL-6 particularly 
important in axis activation during chronic stress [165]. Additionally, eicosanoids, platelet-
activating factor and serotonin act as inflammatory mediators to stimulate the HPA axis [166]. 
Chronic activation of the HPA axis in depression may both directly and indirectly influence 
myocardial phenotype and stress-tolerance (Figs. 1 & 2). 
 Glucocorticoids exert direct cardiovascular effects, including positive inotropism and 
increased blood pressure and cardiac output [167]. They also sensitize the cardiovascular system to 
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catecholamines, and prolong the actions of catecholamines at neuromuscular junctions [163]. 
Coupled with sympathetic over-activation, HPA axis dysfunction may exaggerate the pro-injurious 
actions of catecholamines. In addition, cortisol inhibits insulin and promotes lipolysis, modifying 
substrate metabolism and elevating blood glucose. Chronic stress also induces insulin-resistance, 
further promoting hyperglycemia, with both hyperglycemia and insulin-resistance known to impair 
infarct tolerance and cardioprotective signaling [27-30,168,169]. Similarly, elevations in serum 
fatty acids, particularly saturated forms, may induce myocardial dysfunction and apoptotic death, 
while polyunsaturated fats are protective [170,171]. Whether cortisol-dependent inhibition might 
also limit the cardioprotective action of insulin [89,172] has not been tested.  
 Stimulation of the HPA axis reduces production of thyroid-stimulating hormone and 
conversion of thyroxine to triiodothyronine (Fig. 2), which can lead to sick euthyroid syndrome 
[173], associated with cardiac dysfunction under normoxic and post-ischemic conditions [174]. It is 
less clear whether infarction is sensitive to this imbalance [175], although sick euthyroid syndrome 
is associated with greater in-hospital and long-term mortality in AMI patients undergoing 
percutaneous intervention [176]. Gonadal steroid secretion is also reduced with HPA axis activation 
[163], with evidence maintenance of testosterone levels reduces major adverse cardiovascular 
events and death [177], while protective effects of estrogen are well established [178]. Finally, 
prolonged activation of the HPA axis also inhibits growth hormone secretion and IGF-1 [179], with 
the growth hormone/IGF-1 axis known to reduce CHD risk and protect myocardium against 
infarction [180,181]. This spectrum of neuroendocrine outcomes with HPA axis dysfunction may 
collectively contribute to stress intolerance and other myocardial changes. In turn, HPA axis 
dysfunction has been extensively demonstrated in MDD [26] and other mental illness such as 
anxiety disorders [182,183]. While links between MDD and myocardial damage can be postulated 
in terms of mechanisms of autonomic and HPA axis dysregulation, their individual roles and 
contributions have yet to be detailed. Changes in HPA hormones have potential to modify cell death 
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processes [40], yet no study has confirmed involvement of HPA dysfunction in the effects of MDD 
on myocardial infarct tolerance.   
 
3.4 Immuno-inflammatory function    
 Depression increases pro-inflammatory cytokine production and levels of acute-phase 
proteins, chemokines and adhesion molecules [184-189] (Figs. 1 & 2). Pro-inflammatory cytokines 
(eg. IL-1, IL-6, TNFα) promote fatigue, somnolence and withdrawal from social activity [189-191]. 
Moreover, endotoxin induces anhedonia in rats, coupled with somnolence and reduced exploratory 
and social behavior and food intake [191], and in humans induces anxiety, depressed mood and 
impaired memory function [192]. These symptoms have been termed ‘sickness behavior’ [191-
195], and mirror the neuro-vegetative features of MDD. Importantly, sickness behavior symptoms 
induced with pro-inflammatory cytokines are reversed with anti-depressant medication [190,196]. 
 Stress-dependent modulation of the immune response and pro-inflammatory cytokines also 
increases infection susceptibility [197,198], and in humans chronic stress is associated with 
susceptibility to viral infection, delayed wound healing, and impaired antibody responses to 
vaccination [199,200]. These changes are influenced, in turn, by other elements of the integrated 
network of mechanisms that can result in MDD [26] (Fig. 1). For example, both vagal activity and 
the HPA axis impact immune function and inflammation, and corticosteroids impair humoral 
immunity and increase autoimmune inflammatory responses [201] (Figs. 1 and 2). Long-term 
elevations in cortisol with chronic stress can thus promote autoimmune responses while limiting 
capacity to fight infection. In addition, myocardial apoptosis with endotoxemia appears to be 
promoted by β-adrenergic receptor activity [95], suggesting potential synergism between 
sympathetic activity, immune and inflammatory function in MDD.  
 Pro-inflammatory cytokines are known to exaggerate myocardial damage during infarction, 
although effects are complex with evidence of protective actions of transient elevations in cytokines 
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including TNFα [202], together with roles in promoting post-infarct healing [203-205]. Immune 
function is also a critical determinant of infarct outcomes and cardioprotection [206-209]. While no 
studies have effectively confirmed mechanistic involvement of perturbed inflammation and immune 
function in the impacts of MDD or chronic stress on infarct tolerance, there is evidence for 
inflammatory cell infiltration, activation of inflammatory signaling, and toll-like receptor 4 and 
NFκB dependent myocardial injury in models of chronic stress [41,58]. Chronic stress also 
increases macrophage infiltration and growth and vulnerability of atherosclerotic plaques, in 
association with exaggerated infarct occurrence and injury [210].  
 
4. Animal models of depression and their use in studies of infarct tolerance  
 Modeling human disease in animals poses a major challenge in examining mechanisms 
governing myocardial phenotype in depression. Issues include the perennial complication of 
species-specific biology, and questions regarding the nature of behavioral pathologies induced in 
different models. Importantly, while no single model replicates the range of physiological, 
psychological and social components of human depression, specific animal models do manifest 
important elements of the disorder [211]. As outlined by Willner [39], the validity of animal models 
is determined by 3 characteristics: the model should replicate the symptoms of human depression 
(face validity); model symptoms should involve neurophysiologic mechanisms corresponding to 
those in humans (construct validity); and pharmacological or other interventions should 
appropriately influence behavioral outcomes (predictive validity). Of course, it is problematic to 
ascertain the true construct validity of any animal model while the neurophysiological mechanisms 
underpinning human depression remain poorly defined.  Limitations or complications relevant to all 
such models include evidence of significant strain- [212-216], sex- [46,51,217,218] and age-
dependent [219-222] outcomes and responses to anti-depressants.  
 As the diversity of animal models, their pros, cons and relevance to human depression have 
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been reviewed in detail previously [211,223-225], they are addressed here in brief. Animal models 
of depression may be generally divided according to the means of induction of depressive behavior:  
i) exposure to acute or sub-chronic stress, including the despair-based forced swimming and 
tail suspension test models. However, there are questions regarding the validity of these models, 
and they tend to produce limited and short-lasting depressive-like symptoms. On the other hand, the 
learned helplessness model (discussed below) does generate longer lasting behavioral and cognitive 
changes and appears a more valid model within this sub-set.  
ii) chronic exposure to multiple 'mild' stressors, inducing depressive-like symptoms 
including anhedonia, reduced activity and changes in appetite and weight. It is important to 
recognize, however, that the key behavioral indicator of depressive state in these models  - 
anhedonia-like behavior - is not specific to depression, arising in some other behavioral disorders.  
iii) modulation of select physiologic processes to manifest depressive symptoms and 
examine the molecular pathogenesis of depression (eg. modulating HPA axis or immune function). 
However, considerable heterogeneity in behavioral outcomes may arise in such models, and 
outcomes may also not be specific to depression. 
iv) genetic models [226-228] or surgical manipulations (eg. olfactory bulbectomy [220]) to 
modify phenotype and behavior, again more relevant in investigating specific pathophysiological 
elements of depressive disorders.  
 The three models most widely applied in pre-clinical research in recent years are the chronic 
mild stress, forced swim test, and learned helplessness models [224]. The former is most commonly 
applied in studying myocardial stress responses and infarct tolerance. Analyses of myocardial 
outcomes across a broader range of models are warranted, including effects of the forced swim test 
and learned helplessness models on infarct incidence and tolerance. 
Chronic mild stress. The chronic mild stress model of depression was initially developed 
over 35 years ago [229,230], and has been adapted by investigators in studying multiple aspects of 
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depression including cardiac infarct intolerance [44,48-50]. Greater validity and manifestation of 
long-lasting depressive symptomatology are advantages [39]. The model triggers antidepressant-
sensitive anhedonia-like behavior (assessed from reduced sucrose consumption and preference) and 
other depressive characteristics (reduced exploratory behavior and grooming), together with shifts 
in neurotransmitter signaling. These behaviors are induced over a 3-9 wk induction period in which 
differing stressors are applied in random/semi-random order, limiting capacity to adapt. However, 
widely varying durations of stress across studies may lead to differing outcomes, with the impact(s) 
of stressor duration yet to be adequately examined. The model is considered superior to the learned 
helplessness and forced swim test models in terms of the time-course and specific symptoms of 
depression, and also effects of anti-depressants. Disadvantages are in part practical – the method is 
highly labor intensive, the variety and durations of stress raise ethical concerns and may limit ethics 
approval, and importantly the model can be difficult to establish, with considerable variations in 
outcome despite use of similar protocols [39]. Additionally, repeated stressors (despite 
randomization) have the potential to induce resilient phenotypes, complicating interpretation. 
Commonly incorporated within chronic mild stress models, both crowding [231-233] and restraint 
[234,235] are also employed as individual stressors. However, it is possible resilience/adaptation 
arises, limiting their applicability. Studies do support a greater capacity to trigger depressive 
symptoms with unpredictable forms of stress rather than restraint alone [236], and there is also 
some evidence crowding stress does not alter infarct tolerance [51]. Social isolation as a sole stress 
has also not been examined for effects on myocardial infarct tolerance, through has been 
incorporated with other stressors in studies of chronic mild stress [48-50]. 
 Forced swim test. In this model rodents are forced to swim in a partially fluid-filled cylinder 
in order to survive an inescapable situation. A pre-test swim of ~15 min is thought to induce 
behavioral despair, and is followed 24 hrs later by a brief 5 min session. Instances and duration of 
immobility are used as primary indicators of behavioral despair. Although the forced swim test is 
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widely employed in studies of depression, this is largely a reflection of its simplicity, low cost and 
short experimental duration rather than model validity, which remains questionable [237,238]. 
Indeed, the short induction period contrasts patterns of depression development in humans. 
Moreover, variations in parameters such as number of training sessions, testing durations and 
equipment dimensions can significantly impact outcomes. Nonetheless, the practical aspects of the 
model render it popular in high-throughput screening of anti-depressant responses [239]. The model 
has not yet been applied in studying potential shifts in cardiac infarct tolerance.  
 Learned helplessness. The learned helplessness model is increasingly employed, though yet 
to be applied in studying effects on cardiovascular phenotype and stress tolerance. Helplessness is a 
central feature of clinical depression, and is inducible in animal models. Learned helplessness 
reflects a failure to control unpleasant stimuli, and subsequently avoid stressful events. Unavoidable 
electrical shocks are used to induce helplessness in rodents, leading to development of 'escape 
failure' - a negative coping strategy in which animals no longer avoid stress. The model induces 
depressive symptoms, including anxiety-like behavior, and decreased exploratory behavior,  
locomotion and body growth [240-243]. Nonetheless, it is important to note that inescapable stress 
in humans induces short-term depressive-like symptoms not characteristic of clinical depression. 
Moreover, from a practical perspective relatively little is known regarding impacts of protocol 
variations on behavioral and other outcomes. Despite these limitations, together with the 
complexity of the protocol, need for specialized equipment and application of electrical shocks, 
learned helplessness is arguably one of the more valid animal models of depression [244]. While 
not yet studied for impacts on cardiac stress responses and infarct tolerance, the direct and indirect 
effects of unavoidable electrical shock were recently studied by Rakhshan and colleagues [47]. 
 
4.1. Application in studies of cardiac ischemic tolerance  
Changes in myocardial responses to ischemia-reperfusion have only been assessed in a sub-
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set of these depression models. Inhibitory effects on ischemic tolerance have been demonstrated in 
models of chronic mild stress that include: 20 day administration of stressors (daylight/darkness 
exposure, overcrowding, isolation, new hierarchy, cage tilting, restriction of water or food)  [44]; or 
21 days of randomized stressors (confinement to a small cage, restraint, water deprivation, food 
deprivation, isolation, flashing light, forced cold water swimming, group-housing in a soiled cage) 
[48-50]. Scheuer et al. tested the effects of chronic (1-2 hrs/day for up to 14 days) restraint stress 
[42], while crowding stress was assessed by Ravingerova et al. (living space reduced from 480 
cm2/rat to 200 cm2/rat for 8 wks) [45] and Ledvenyiova-Farkasova et al. (living space reduced from 
200 to 70 cm2/100 g body mass for 2 weeks) [51]. Rakhshan et al. employed a model of daily 
electrical shocks (over a 1 hr period/day for 1 wk) or witnessing shocks in communal housing [47], 
mimicking in part elements of the learned helplessness model. As detailed above, these forms of 
chronic stress increase both infarction and contractile dysfunction [42,47], or selectively influence 
contractile recovery [45,51]. Infarct intolerance is also evident in stress models reflective of other 
disorders, including sleep deprivation [56] and a predator/stress model of PTSD [46]. Interestingly, 
2 weeks of crowding stress studied by Ledvényiová-Farkašová and colleagues [51] failed to 
influence infarct tolerance in normotensive animals, though selectively reduced contractile 
recoveries in female hearts (association with reduced NOS activity). This contrasts outcomes in 
models of restraint stress [42], chronic mild stress [40,44,48-50] and physical and psychological 
stress [47], suggestive of a lesser cardiac impact of crowding. Although it has been noted that 
chronic stress can yield mixed results in terms of myocardial infarct tolerance [52], this may reflect 
differing cardiovascular responses to metabolic vs. psychologic stressors. For example, both short-
term and chronic hypoxic stressors are cardioprotective [245], as are brief and chronic caloric 
limitation [246] or physical exercise [247]. However, in the case of chronic ‘forced’ exercise, 
attendant psychological stress may contribute to cardiac detriment that is resistant to metabolic 
modulation [248].  
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 A key limitation in a number of these investigations is failure to undertake behavioral 
assessment to confirm depressive states prior to myocardial insult. The studies in which behavioral 
responses were validated prior to ischemic injury include those of chronic mild stress by Wang et 
al. [48-50] and Xingxing et al. [40], and the work of Rorabaugh and colleagues in a model of PTSD 
[46]. No behavioral outcomes were assessed in other studies of the cardiac impacts of chronic mild 
stress [44], or chronic physical or psychological [47], restraint [43] or crowding [45] stress. Studies 
of other negative cardiovascular consequences of stress also fail to adequately assess associated 
behavioral changes [58].	
 
5. Relevance to clinical cardioprotection  
Beyond reducing the risk and prevalence of CHD, a long-running and intractable challenge 
in cardiology has been the development of cardioprotective therapy to limit myocardial injury with 
AMI or ischemic surgery [28-30,249]. Early reperfusion remains the sole approach to salvage 
ischemic tissue, yet itself induces additional damage, and benefit remains variable and highly time-
sensitive. There are few clinical scenarios in which outcome is so critically time-dependent: 
reperfusion is optimal within a 1.5-2 hr window that is rarely achieved in AMI - most Australians 
for example are reperfused >2.5 hrs from symptom onset, with less than 25% receiving ‘timely’ 
reperfusion [250]. Even optimally timed reperfusion yields highly variable outcomes [251]. As we 
and others argue [27-30], failure to clinically translate cardioprotection reflects in part failure to 
address the negative influences of aging, drugs and common co-morbid conditions (including 
atherosclerosis, obesity, diabetes, hypertension) on the myocardial defense mechanisms targeted by 
widely studied and trialed interventions. Though highly effective in young healthy hearts, many 
cardioprotective interventions appear less effective (if at all) in older hearts or in the presence of 
other co-morbid conditions. Depression is thus a key co-morbidity that has received even less 
attention than aging, obesity, diabetes or hypertension. Approximately 20% of CHD patients suffer 
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from MDD [8,34], while up to 25%  of patients suffer depression post-infarction [252]. Thus, 
approaches to both acute protection against AMI and also later protection against delayed injury 
and remodeling may be significantly impacted.  
The depressed CHD patient may pose a particularly problematic challenge. Protection via 
pre-conditioning may require cardiac nerve activity [105], although this remains contentious [101], 
and both vagal activity [142-144] and sympathetic signaling [106,107,253,254] have been 
implicated in ischemic pre- and post-conditioning responses. Thus, the sympathetic and vagal 
dysfunction potentially worsening infarct tolerance with depression may render these hearts less 
responsive to conditioning interventions. The effects of MDD and chronic stress on the expression 
and functionality of protective signaling pathways engaged by these stimuli, including the 
‘reperfusion injury salvage kinase’ or RISK path [255], and the ‘survivor activating factor 
enhancement’ or SAFE path [202], are largely unstudied. To date only one investigation has 
directly tested the effects of depression on conditioning responses, supporting inhibition of ischemic 
post-conditioning in a rat model of chronic mild stress, potentially involving impaired post-
ischemic activation of protein kinase B and STAT-3 [256]. Curiously, the study did not identify any 
impact of chronic mild stress on infarct size is non-preconditioned hearts, contrary to other reports 
of exaggerated cell death and infarction in similar models [40,44,48-50].    
 
6.  Myocardial effects of anti-depressants 
 Interactions between mood and cardiac phenotype are further evidenced by beneficial 
myocardial effects of anti-depressants [257], which can also improve AMI outcomes and CHD 
mortality [258]. However, it is important to highlight that to date no fully powered study has 
confirmed that anti-depressant (or psycho) therapy improves survival following AMI. Although 
consistent with the detrimental cardiac impacts of depression, interpretation of the above findings is 
complicated by pleiotropic cardioprotective effects of such agents [259,260]. Moreover, other 
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agents exhibiting cardioprotective actions also mediate anti-depressant effects (eg. resveratrol 
[261]), supporting a broad influence of cardiovascular health on depression. A detailed analysis of 
the cardioprotective effects of anti-depressants is needed, in particular identifying the molecular 
mechanisms of such effects, and whether these agents can act directly on the myocardium, 
independently of effects within the central nervous system.     
 
7.  Concluding remarks 
 In summary, studies to date indicate that models of depression worsen myocardial death and 
dysfunction following ischemia or infarction. However, there is a need to perform studies in a 
broader range of animal models (with behavioral outcomes confirmed), and the upstream mediators 
and molecular basis of myocardial changes remain to be detailed. In terms of neurohumoral 
mediators, there is some limited evidence for involvement of sympathetic over-activity [47], 
coupled with indirect evidence implicating catecholamines and 5-HT [40]. Further delineation of 
the roles of the major components of the PINE network - the autonomic nervous, immune and 
inflammatory systems, and the HPA axis - in inducing myocardial infarct intolerance with MDD is 
critical in understanding the reciprocal relationship between MDD and CHD. At the level of the 
myocardium itself, we also have a rather basic view of alterations in chronic stress models of MDD 
(or indeed MDD patients), with injury end-points primarily assessed to date. These studies support 
exaggerated oxidative and nitrosative damage [44], altered expression of Bcl-2 proteins and 
increased apoptosis and infarction [48-50], leaving the regulatory or signaling basis somewhat 
obscure: how are molecular oxidative and nitrosative damage exaggerated, Bcl-2 proteins and 
apoptosis pathways modified, and infarction worsened by MDD? Equally important -  how does 
chronic stress or MDD influence the heart’s intrinsic cytoprotective mechanisms and 
responsiveness to cardioprotective therapies.  A single study indicates depression negates the ability 
of ischemic post-conditioning to limit infarction in rats [256], suggesting that depressive states may 
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be an additional factor in the inability of cardioprotective stimuli to limit infarction in those 
suffering CHD [29,30,249]. Identifying specific myocardial modifications underlying impaired 
infarct tolerance can facilitate development of approaches to improving cardiac phenotype and 
ischemic outcomes in this significant patient population.  
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FIGURES 
Fig. 1. Directional network map highlighting the pathways linking chronic stress and MDD to 
multiple mechanisms of cardiac pathology. Biological systems (boxes) which are nodes in the 
network are depicted in different colors (endocrine mechanisms, purple; autonomic activity, yellow; 
inflammatory mechanisms, green; mechanisms relating to both cardiac tissues and function, red). 
Arrows are colored according effects on target nodes (promotes = blue; inhibits = red). 
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Fig. 2.  Potential signaling governing myocardial stress phenotype in MDD. Within  
myocardium MDD/stress impairs infarct tolerance and cardioprotection, in association with 
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exaggerated nitrosative/oxidative damage, altered expression of apoptotic mediators and increased 
apoptosis. The basis of these direct myocardial changes remains unclear. MDD (and chronic stress 
models of MDD) are associated with sympathetic activation vs. vagal suppression, HPA axis 
dysfunction, inflammation and immunomodulation. The HPA axis dysfunction: elevates adrenal 
glucocorticoid (eg. cortisol) secretion via hypothalamic corticotropin release hormone (CRH) and 
anterior pituitary adrenocorticotropic hormone (ACTH) release; suppresses gonadal hormone 
production (testosterone, estrogen) via reduced hypothalamic gonadotropin releasing hormone 
(GnRH) and pituitary gonadotropin (LS, FSH) secretion; and suppresses thyroid thyroxine (T4) and 
circulating triiodothyronine (T3) levels, and hepatic insulin-like growth factor-1 (IGF-1) release via 
reductions in pituitary thyroid-stimulating hormone (TSH) and growth hormone (GH) secretion, 
respectively. Vagal activity directly impacts the heart, and modifies stress responses/remodeling via 
the cholinergic anti-inflammatory reflex (including inhibition of macrophage/inflammatory cell 
cytokine generation via α7 nicotinic receptors - α7). Sympathetic activity also directly impacts the 
heart while influencing cytokine/substance P release from inflammatory cells, B cell antibody 
production, and acetylcholine (Ach) release from choline acetyl-transferase expressing T cells. 
Cytokines/inflammation in turn signal to the central nervous system via vagal and sensory afferent 
fibers (not shown). Metabolic changes with altered cortisol, catecholamines, T3 and GH include 
insulin-resistance, hyperglycemia, lipolysis and elevated circulating free fatty acids (FFAs). Which 
of this array of neurohumoral, inflammatory and immune factors are key in inhibiting  myocardial 
stress resistance remains to be established.  
 
 
 
 
 
 
 
	 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Environmental enrichment may mimic the cardioprotection with physical exercise in mice. 
These unpublished data show effects of environment enrichment (initial placement of a locked 
running wheel in the cage for 2 days) compared with 7 days of voluntary wheel running in 
Langendorff perfused hearts isolated from these mice [54]:  phospho-activation of myocardial AKT 
(pro-survival); phospho-inhibition of GSK3β (pro-injury); and functional recovery from 25 min 
global ischemia and 45 min reperfusion (% recovery of left ventricular pressure development, 
LVDP). Note the similar signalling and cardioprotective outcomes with both active wheel-running 
and simple environment enrichment. Data are means±SEM (n=6-7).  
